AstraZeneca Signs Exclusive Worldwide License Agreement with Accent for RMP-Targeting Therapies

 AstraZeneca Signs Exclusive Worldwide License Agreement with Accent for RMP-Targeting Therapies

AstraZeneca Signs Exclusive Worldwide License Agreement with Accent for RMP-Targeting Therapies

Shots:

  • Accent to receive $55M upfront and $1.1B as co-development option and milestone payment, plus royalties and profit split based on the option to co-develop and co-commercialize RMP-targeting therapies for the treatment of cancer in the US
  •  Accent will be responsible for research and development activities for a nominated preclinical program through to the end of P-I clinical trials. Post-P-I completion, AstraZeneca will lead development and commercialization activities for the nominated program, with Accent having the option to jointly develop and commercialize with AstraZeneca in the US
  • The collaboration combines Accent’s expertise as a leader in the biology, target identification and drug discovery of RMP-targeting therapies with AstraZeneca’s expertise in oncology. Additionally, AstraZeneca is having an option to license two additional preclinical discovery programs, for which Accent will conduct preclinical activities

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image:  AstraZeneca

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post